Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children

Journal of Clinical Pharmacology

Volumn 43, Issue 4, 2003, Pages 386-396

  Agbenyega, Tsiri ^a,b   Planche, Tim ^c   Bedu Addo, George ^b   Ansong, Daniel ^b   Owusu Ofori, Alex ^b   Bhattaram, Venkatesh A ^d   Nagaraja, Nelamangala V ^d   Shroads, Albert L ^e   Henderson, George N ^e   Hutson, Alan D ^e   Derendorf, Hartmut ^d   Krishna, Sanjeev ^c   Stacpoole, Peter W ^d,e  

^a KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^b KOMFO ANOKYE TEACHING HOSPITAL   (Ghana)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Dichloroacetate; Lactic acidosis; Malaria; Pharmacodynamics; Population pharmacokinetics

Indexed keywords

DIAZEPAM; DICHLOROACETIC ACID; GLUCOSE; LACTIC ACID; PHENOBARBITAL; QUININE; THIAMINE;

ACID BASE BALANCE; AFRICA; ANEMIA; ARTICLE; ATAXIA; BLOOD SAMPLING; BLOOD TRANSFUSION; BRAIN MALARIA; CHILD CARE; CLINICAL TRIAL; COMA; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOCAL EPILEPSY; GRAND MAL SEIZURE; HUMAN; HYPOGLYCEMIA; HYPOTENSION; IN VIVO STUDY; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALARIA; MALE; MORTALITY; MUSCLE WEAKNESS; PHARMACODYNAMICS; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT;

ACIDOSIS, LACTIC; ANTIMALARIALS; CHILD, PRESCHOOL; DICHLOROACETATE; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALARIA, FALCIPARUM; MALE; MODELS, BIOLOGICAL; QUININE; TIME FACTORS;

EID: 0037381682     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003251392     Document Type: Article

References (30)

1. Sturchler D, Mittelholzer ML, Handschin J: Commitment of Roche in malaria and other tropical diseases. Trop Med Parasitol 1993; 44:250-253.
2. White NJ, Warrell DA, Looareesuwan S, Chanthavanich P, Phillips RE, Pongpaew P: Pathophysiological and prognostic significance of cerebrospinal-fluid lactate in cerebral malaria. Lancet 1985;1: 776-778.
3. Krishna S, Waller DW, ter Kuile F, Kwiatkowski D, Crawley J, Craddock CF, Nosten F, et al: Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance. Trans R Soc Trop Med Hyg 1994;88:67-73.
4. Day NP, Phu NH, Mai NT, Chau TT, Loc PP, Chuong LV, et al: The pathophysiologic and prognostic significance of acidosis in severe adult malaria. Crit Care Med 2000;28:1833-1840.
5. Newton CR, Krishna S: Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment. Pharmacol Ther 1998;79:1-53.
6. Pukrittayakamee S, White NJ, Davis TM, Looareesuwan S, Supanaranond W, Desakorn V, et al: Hepatic blood flow and metabolism in severe falciparum malaria: clearance of intravenously administered galactose. Clin Sci (Lond) 1992;82:63-70.
7. Krishna S, Taylor AM, Supanaranond W, Pukrittayakamee S, ter Kuile F, Tawfiq KM, et al: Thiamine deficiency and malaria in adults from southeast Africa. Lancet 1999;353:546-549.
8. Stacpoole PW: Lactic acidosis. Endocrinol Metab Clin North Am 1993;22:221-245.
9. ter Kuile F, White NJ, Holloway P, Pasvol G, Krishna S: Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol 1993;76:85-95.
10. Stacpoole PW, Barnes CL, Hurbanis MD, Cannon SL, Kerr DS: Treatment of congenital lactic acidosis with dichloroacetate. Arch Dis Child 1997;77:535-541.
11. Stacpoole PW: Lactic acidosis and other mitochondrial disorders. Metabolism 1997;46:306-321.
12. Stacpoole PW, Henderson GN, Yan Z, Cornett R, James MO: Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab Rev 1998;30:499-539.
13. Stacpoole PW: The pharmacology of dichloroacetate. Metabolism 1989;38:1124-1144.
14. Krishna S, Supanaranond W, Pukrittayakamee S, Karter D, Supputamongkol Y, Davis TM, et al: Dichloroacetate for lactic acidosis in severe malaria: a pharmacokinetic and pharmacodynamic assessment. Metabolism 1994;43:974-981.
15. Krishna S, Supanaranond W, Pukrittayakamee S, Kuile FT, Ruprah M, White NJ: The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. Br J Clin Pharmacol 1996;41:29-34.
16. Krishna S, Agbenyega T, Angus BJ, Bedu-Addo G, Ofori-Amanfo G, Henderson G, et al: Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria. Q J Med 1995;88:341-349.
17. Agbenyega T, Angus BJ, Bedu-Addo G, Baffoe-Bonnie B, Guyton T, Stacpoole PW, et al: Glucose and lactate kinetics in children with severe malaria. J Clin Endocrinol Metab 2000;85:1569-1576.
18. Holloway PA, Knox K, Bajaj N, Chapman D, White NJ, O'Brien R, et al: Plasmodium berghei infection: dichloroacetate improves survival in rats with lactic acidosis. Exp Parasitol 1995;80:624-632.
19. Krishna S, Nagaraja NV, Planche T, Agbenyega T, Bedo-Addo G, Ansong D, et al: Population pharmacokinetics of intramuscular quinine in children with severe malaria. Antimicrob Agents Chemother 2001;45:1803-1809.
20. Molyneux ME, Taylor TE, Wirima JJ, Borgstein A: Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. Q J Med 1989;71:441-459.
21. Curry SH, Lorenz A, Chu PI, Limacher M, Stacpoole PW: Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses. Biopharm DrugDispos 1991;12:375-390.
22. Beal SL, Sheiner LB: NONMEM Users Guides. Hanover, MD: Globomax LLC, 1989-1998.
23. Kowalski KG, Hutmacher MM: Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study. Stat Med 2001;20:75-91.
24. Jonsson EN, Karlsson MO: Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NOMEN. Comput Methods Programs Biomed 1999;58:51-64.
25. Jusko WJ, Ko HC: Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994;56:406-419.
26. Chan PL, Holford NH: Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol 2001;41:625-659.
27. Chu PI, Curry SH, Baumgartner TG, Henderson GN, Stacpoole PW: Preparation and stability of intravenous solutions of sodium dichloroacetate (DCA). J Parenter Sci Technol 1992;46:16-18.
28. Fox AW, Sullivan BW, Buffini JD, Neichin ML, Nicora R, Hoehler FK, et al: Reduction of serum lactate by sodium dichloroacetate, and human pharmacokinetic-pharmacodynamic relationships. J Pharmacol Exp Ther 1996;279:686-693.
29. Williams PJ, Lane JR, Turkel CC, Capparelli EV, Dziewanowska Z, Fox AW: Dichloroacetate: population pharmacokinetics with a pharmacodynamic sequential link model. J Clin Pharmacol 2001;41: 259-267.
30. Shangraw RE, Fisher DM: Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis. Clin Pharmacol Ther 1999;66:380-390.